MaRS places Israeli biotech veteran at helm

Hofstein%2CDr%2CRaphael-cropped.jpgTORONTO – MaRS Innovation names Dr. Raphael Hofstein (pictured) as president and CEO. Dr. Hofstein comes to MaRS Innovation by way of Israel, where he was president and CEO of tech transfer company Hadasit Ltd.
“We are delighted to welcome Dr. Hofstein,” says Mary Jo Haddad, chair of MaRS Innovation, which is a subset of the Queen’s Park-sponsored innovation hub MaRS Discovery District. “His outstanding credentials and experience stood out in our extensive international search. He is exceptionally qualified to build and lead this important partnership.”
Before his time at Hadasit, Dr. Hofstein was president of Mindsense Biosystems Ltd., which develops neuropsychiatric immune assays. Prior to that he was VP of business development at Ecogen Inc.. a subsidiary of Monsanto. His portfolio includes numerous directorships past and present, among them board member of the Israeli Life Science Industry Organization, of which he is a co-founder. He also served as chairman of BIOMED, Israel’s annual biomedical conference, from 2005 to 2007.
“MaRS Innovation is a unique global initiative … to strengthen commercialization output,” says Dr. Hofstein. “In my experience, good science is the single most important ingredient for success in this business. Toronto is already known as one of the strongest science cities in the world, and it continues to grow. Leading MaRS Innovation is a wonderful opportunity to do something remarkable.” Dr. Hofstein received his PhD and Master of Science degree from the Weizmann Institute of Science in Rehovot, Israel, where he was awarded the Chaim Weizmann Postdoctoral Fellowship. He continued his post-doctoral work at the Harvard Medical School in Boston.

Submit a comment

Please leave your name, which will be used to sign your submission to the SCANsite. Thanks for contributing your thoughts. Come back again. Tony Patterson, Editor & CEO.

© 2006 - 2009 SCAN
Site by Citadel Rock